

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Zhou, et al.

Docket No.: **HMV-043.01**

Appln. No.: 09/415,795

Filed: October 8, 1999

For: *TARGETED PROTEOLYSIS BY RECRUITMENT
TO UBIQUITIN PROTEIN LIGASES*

Assistant Commissioner for Patents
Washington, D.C. 20231
Attn: Application Processing Division
Correction Branch



RECEIVED
MAR 27 2000
TC 1600 MAIL ROOM

Certificate of First Class Mailing

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, Attn: Application Processing Division/Correction Branch on:

March 16, 2000
Date

Jonathan Furtado
Jonathan Furtado

REQUEST FOR CORRECTION OF FILING RECEIPT

Dear Sir:

Applicants request the following information be added to the Filing Receipt for the above-referenced patent application:

CONTINUING DATA AS CLAIMED BY APPLICANT:

THIS APPLN CLAIMS PRIORITY TO 60/103,787 10/09/98

Applicants submit that there is no fee due for this Request, as this was not Applicant's error. However, should this be incorrect, the Commissioner is hereby authorized to charge our Deposit Account No. 06-1448 for this fee.

Respectfully submitted,

I. Clauss
Isabelle M. Clauss, Ph.D.
Reg. No. (see attached)
Agent for Applicant

Patent Group
FOLEY HOAG & ELIOT, LLP
One Post Office Square
Boston, MA 02109
Tel. 617-832-1000
Fax 617-832-7000

Dated: March 14, 2000

FILING RECEIPT
CORRECTED



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/415,795	10/08/99	1632	\$1,750.00	HMV-043.01	12	36	7

MATTHEW P VINCENT ESQ
FOLEY HOAG & ELIOT LLP
ONE POST OFFICE SQUARE
BOSTON MA 02109-2170



Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts of Application" ("Missing Parts Notice") in this application, please submit any corrections to this Filing Receipt with your reply to the "Missing Parts Notice." When the PTO processes the reply to the "Missing Parts Notice," the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) PENGBO ZHOU, CHESTNUT HILL, MA; PETER HOWLEY, WELLESLEY, MA.

CONTINUING DATA AS CLAIMED BY APPLICANT:

THIS APPLN CLAIMS PRIORITY TO 60/103,787 10/09/98

IF REQUIRED, FOREIGN FILING LICENSE GRANTED 11/10/99

TITLE

TARGETED PROTEOLYSIS BY RECRUITMENT TO UBIQUITIN PROTEIN LIGASES

PRELIMINARY CLASS: 435

Corr Filing Recept
DOCKETED
DUE: 3-17-00

Corr
Date

RECEIVED

FEB 17 2000

PATENT DEPT.
DOCKETING

DATA ENTRY BY: DUNCAN, KIMBERLY

TEAM: 04 DATE: 02/10/00



LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "FOREIGN FILING LICENSE GRANTED" followed by a date appears on the reverse side of this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.11. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR Parts 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "FOREIGN FILING LICENSE GRANTED" DOES NOT appear on the reverse side of this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE ---- The Following Information about the Filing Receipt:

The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.

The words "new," "improved," "improvement," "improvements in or relating to" are not included as the first words in the title of an application because a patent application is, by nature, a new idea or improvement.

The title may be truncated if it consists of more than 4 lines of 70 characters each (letters and spaces combined).

The inventor information may be truncated if the family name consists of more than 25 characters (letters and spaces combined) and if the given name consists of more than 25 characters (letters and spaces combined). The inventor's residence allows for up to 40 characters (letters and spaces combined).

The docket number allows a maximum of 12 characters.

If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Customer Address may have been modified to conform to U.S. Postal rules.

Please direct correction, including a copy of your Filing Receipt, to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231